Please assess the completion status of the following clinical trial:

Trial Title: Phase II Study of Doxorubicin and Avastin® in Sarcoma.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Pathologically confirmed intermediate or high grade locally advanced or metastatic soft tissue sarcoma.~2. The presence of measurable disease~3. Normal renal function (spot dipstick \<2\*\* or urine protein: creatinine ratio \>1.0~4. Normal Hepatic function (total bilirubin within JOHC normal limits, transaminases (AST and ALT \<3 times upper limit of normal~5. Hematologic parameters as defined as ANC \>1500/mm³ and Platelets \> 100,000/mm³.~6. Performance status 0-1 on ECOG scale~7. Use of effective means of contraception (men and women) in subjects of child-bearing age~8. No prior use of mesna, adriamycin, ifosfamide or Avastin®.~9. Baseline ECHO or MUGA with LVEF \> or = 50-60%.~10. Age ≥ 18~Exclusion Criteria:~1. Major surgery within 28 days~2. History of proteinuria \> 1+~3. Current, recent (within 4 weeks of the first infusion of this study), or planned participation in an experimental drug study other than a Genentech-sponsored Avastin® cancer study~4. Inadequately controlled hypertension (defined as systolic blood pressure \>150 and/or diastolic blood pressure \> 100 mmHg on antihypertensive medications)~5. Any prior history of hypertensive crisis or hypertensive encephalopathy~6. New York Heart Association (NYHA) Grade II or greater congestive heart failure (see Appendix E)~7. History of myocardial infarction or unstable angina within 6 months prior to study enrollment~8. History of stroke or transient ischemic attack within 6 months prior to study enrollment~9. Symptomatic peripheral vascular disease~10. Significant vascular disease (e.g., aortic aneurysm, aortic dissection)~11. Evidence of bleeding diathesis or coagulopathy~12. Current or recent (within 10 days of enrollment) use of aspirin (\>325 mg/day) or chronic use of other NSAIDs~13. Current, ongoing treatment with full-dose warfarin or its equivalent (i.e., unfractionated and/or low molecular weight heparin).~14. Known central nervous system or brain metastases~15. Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to Day 0, anticipation of need for major surgical procedure during the course of the study~16. Core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within 7 days prior to study enrollment~17. Pregnant (positive pregnancy test) or lactating~18. Proteinuria :creatinine (UPC) ratio ≥ 1.0 at screening or Urine dipstick for proteinuria ≥ 2+ (patients discovered to have ≥2+ proteinuria on dipstick urinalysis at baseline should undergo a 24 hour urine collection and must demonstrate ≤ 1g of protein in 24 hours to be eligible).~19. History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to Day 0~20. Serious, non-healing wound, ulcer, or bone fracture~21. Known hypersensitivity to any component of Avastin®~22. Inability to comply with study and/or follow-up procedures

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Avastin and Doxorubicin (Type: EXPERIMENTAL): Patients will be treated with Avastin 15 mg/kg IV infusion plus doxorubicin 60 mg/M2 (body surface area) IV 6-hour infusion on Day 1 of each 21-day treatment cycle. Dose reductions/modifications will be applied as indicated by toxicities and/or patient tolerance.

Based on this trial design, predict the completion outcome and termination type (if applicable).